A predictive medicine product for hereditary breast and ovarian cancer.
A personalized medicine product to measure a patient's exposure to 5-FU chemotherapy.
A predictive medicine product for hereditary colorectal and uterine cancer.
A personalized medicine product to assess the status of the PTEN gene.
A predictive medicine product for adenomatous polyposis colon cancer syndromes.
A personalized medicine product to predict toxicity to 5-FU-based chemotherapy.
A predictive medicine product for hereditary melanoma.
A prognostic medicine product for prostate cancer.
A predictive medicine product for hereditary pancreatic and related cancers.
Myriad Genetics is a healthcare company focused on the development and marketing of novel molecular diagnostic products. We are committed to improve patient healthcare through the commercialization of predictive medicine, personalized medicine, and prognostic medicine products.
View all releases >>